Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Inventory Average (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Inventory Average for 15 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • Quarterly Inventory Average fell 31.85% to $10.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.5 million through Dec 2025, down 31.85% year-over-year, with the annual reading at $11.6 million for FY2025, 38.98% down from the prior year.
  • Inventory Average hit $10.5 million in Q4 2025 for Ligand Pharmaceuticals, down from $13.7 million in the prior quarter.
  • In the past five years, Inventory Average ranged from a high of $38.4 million in Q2 2021 to a low of $10.5 million in Q4 2025.
  • Historically, Inventory Average has averaged $22.2 million across 5 years, with a median of $21.6 million in 2023.
  • Biggest five-year swings in Inventory Average: skyrocketed 597.5% in 2021 and later crashed 48.42% in 2023.
  • Year by year, Inventory Average stood at $30.2 million in 2021, then tumbled by 40.95% to $17.8 million in 2022, then soared by 38.58% to $24.7 million in 2023, then crashed by 37.49% to $15.4 million in 2024, then tumbled by 31.85% to $10.5 million in 2025.
  • Business Quant data shows Inventory Average for LGNDZ at $10.5 million in Q4 2025, $13.7 million in Q3 2025, and $15.1 million in Q2 2025.